证券代码：605388 证券简称：均瑶健康 公告编号：2023-047 湖北均瑶大健康饮品股份有限公司 2023 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十二 号——酒制造》的相关规定，现将湖北均瑶大健康饮品股份有限公司（以下简称 "公司"）2023 年半年度主要经营数据（未经审计）公告如下： 注：为更清晰的反应公司整体经营活动现金流量特征，根据企业会计准则及 相关规定，并参考部分同类公司的做法，公司 2022 年四季度将部分业务改为净 额法编报，同步修改 2022 年前三季度可比报表营业收入，故本期同时调整本公 告 2022 年 1-6 月相应数据，下同。 2、按区域分类情况： 单位：元 单位：元 产品类别 2023 年 1-6 月主 营业务收入 2022 年 1-6 月主 营业务收入 变动比例 （%） 乳酸菌饮品 342,887,083.50 325,129,607.24 5.46 益生菌饮品 12,374,651.06 1 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-050 湖北均瑶大健康饮品股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日（星期四）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 投资者可于 2023 年 09 月 07 日(星期四)至 09 月 13 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2023 年 08 月 25 日发布《公司 2023 年半年度报告》，为便于广大投资者更全面深入地了解 公司 2023 年半年 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-044 湖北均瑶大健康饮品股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为 289,141,717 股。 本次股票上市流通总数为 289,141,717 股。 本次股票上市流通日期为 2023 年 8 月 18 日。 一、本次限售股上市类型 湖北均瑶大健康饮品股份有限公司（以下简称"均瑶健康"或"公司"）经中 国证券监督管理委员会（以下简称"中国证监会"）《关于核准湖北均瑶大健康饮 品股份有限公司首次公开发行股票的批复》（证监许可[2020]1568 号）核准，首次 公开发行人民币普通股（A 股）股票 70,000,000 股，并于 2020 年 8 月 18 日在上海 证券交易所上市。首次公开发行完成后，公司总股本增加至 430,000,000 股，其中， 有限售条件流通股股份数量为 360,000,000 股，无限售条件流通股股份数量 ...

国泰君安证券股份有限公司、爱建证券有限责任公司 关于湖北均瑶大健康饮品股份有限公司 首次公开发行股票部分限售股解禁上市流通的核查意见 国泰君安证券股份有限公司、爱建证券有限责任公司(以下简称"联合保荐机构") 作为湖北均瑶大健康饮品股份有限公司(以下简称"均瑶健康"或"公司")首次公开发 行股票并上市的持续督导联合保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所股票上市规则》以及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定，对均瑶健康首次公开发行股票部分限售股份解禁 上市流通事项进行了核查，核查情况及核查意见如下： 一、本次限售股上市类型 均瑶健康经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准湖 北均瑶大健康饮品股份有限公司首次公开发行股票的批复》（证监许可[2020]1568 号）核准，首次公开发行人民币普通股（A 股）股票 70,000,000 股，并于 2020 年 8 月 18 日在上海证券交易所上市。首次公开发行完成后，公司总股本增加至 430,000,000 股，其中，有限售条件流通股股份数量为 360,000,000 股，无限售条件 流 ...

关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 31 日（星期三）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 证券代码：605388 证券简称：均瑶健康 公告编号：2023-034 湖北均瑶大健康饮品股份有限公司 投资者可于 2023 年 5 月 30 日(星期二)16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发布公司 2022 年度报告，于 2023 年 4 月 26 日发布公司 2023 年第一季度 报告，为便于广 ...

2023 年第一季度报告 证券代码：605388 证券简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | | --- | --- | --- | --- | --- | | 营业收入 | 445,358,945.57 | | | 102.84 | | 归属于上市公司股东的净利润 | 23,916,582.84 | | | 30.88 | | 归属于上市公司股东的扣除非经常性 损益的净利润 | 18,560,195.20 | | | ...

Financial Performance - In 2022, the company achieved a net profit attributable to all shareholders of RMB 76,631,268.40, with a total distributable profit of RMB 418,893,647.68 at the end of the reporting period[5]. - The company's operating revenue for 2022 was CNY 986,104,247.74, representing a year-on-year increase of 7.94% compared to CNY 913,598,918.70 in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 76,631,268.40, a decrease of 47.87% from CNY 146,987,705.81 in 2021[26]. - The basic earnings per share for 2022 was CNY 0.18, down 47.06% from CNY 0.34 in 2021[28]. - The cash flow from operating activities for 2022 was CNY 179,878,265.00, a significant decrease compared to CNY 81,721,356.48 in 2021, reflecting a decline of 258.10%[26]. - The company's net assets attributable to shareholders at the end of 2022 were CNY 1,921,191,424.25, a slight decrease of 0.93% from CNY 1,930,840,672.63 at the end of 2021[26]. - The weighted average return on equity for 2022 was 3.99%, down from 7.33% in 2021, a decrease of 3.34 percentage points[28]. - The company reported a significant increase in costs due to higher raw material prices and increased investment in probiotic products, impacting net profit[29]. - The fourth quarter of 2022 saw a net profit of CNY -2,279,853.50, contrasting with profits in the previous three quarters[31]. Dividend Policy - The proposed cash dividend for 2022 is RMB 1.00 per 10 shares (including tax), amounting to a total of RMB 43,000,000 (including tax), resulting in a cash dividend payout ratio of 56.11%[5]. - The company maintains a stable dividend distribution policy to protect investors' legitimate rights and interests[5]. Market and Product Development - The company plans to continue focusing on product development and market expansion to improve future performance[29]. - The company's probiotic business achieved sales revenue exceeding 80 million yuan, representing a year-on-year growth of 43%[41]. - The new product "Post-meal Light Body" became the second product after "Taste Power 330" to exceed 100 million yuan in sales, indicating strong growth potential[41]. - The company launched 72 new SKUs in the probiotic product line, transitioning from a steady pace to a "small steps, quick runs" approach in product innovation[42]. - The number of new retail channels, including urban CVS and vending machines, increased by 11,000 by the end of 2022, enhancing market coverage[41]. - The company's e-commerce sales grew by 46%, with 18 official stores established across various platforms including Tmall and JD[42]. Strategic Initiatives - The company signed strategic cooperation agreements with universities to enhance its innovation capabilities in the health industry[42]. - The company established a "Probiotics & Postbiotics Health Functional Food Innovation Center" in collaboration with Northeast Agricultural University and Shanghai University of Science and Technology to promote sustainable development in the health food industry[43]. - The acquisition of Junyao Runying, a leading domestic probiotics manufacturer, added over 30 local probiotic strains and a resource library of more than 4,000 proprietary strains, enhancing the company's industry position[43]. - The company aims to develop Junyao Runying into the largest and most competitive probiotics raw material leader in China within three years, leveraging its core capabilities in the Shanghai market[44]. Operational Efficiency - The company operates its own factories in Yichang, Hubei, and Quzhou, Zhejiang, but faces capacity constraints that limit production during peak seasons[52]. - The company utilizes a contract manufacturing model to supplement its production capacity, ensuring a steady supply of products to meet market demand[52]. - The company has established a comprehensive sales network focused on second- and third-tier cities, developing a single distributor per region to enhance marketing efficiency[53]. - The company has invested significantly in R&D to improve production processes and ensure the stability and advancement of its technology[55]. - The company has formed an integrated supply chain for probiotics, covering raw material production to end-product manufacturing, enhancing its competitive edge in the market[55]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[9]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company acknowledges risks from intensified market competition and fluctuating raw material prices, particularly in the probiotic beverage sector[133]. - The company has established a comprehensive quality control system covering procurement, production, storage, distribution, and sales to address food safety risks[134]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present at the board meeting[8]. - The company has committed to strict compliance with the regulatory requirements and will submit a rectification report within the specified timeframe[157]. - The company has implemented a robust internal control system, with no significant deficiencies reported during the evaluation period[183]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, linking operational indicators to annual business goals[182]. Social Responsibility - The company has committed to social responsibility by donating 60 million yuan worth of probiotic drinks to support disaster relief efforts[189]. - The company has established a long-term poverty alleviation mechanism through employment and development initiatives, benefiting local communities[190].

Financial Performance - The company's revenue for Q3 2022 reached ¥303,971,479.03, representing a year-on-year increase of 35.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥33,489,385.99, a significant increase of 71.55% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥28,138,724.03, up 82.06% year-on-year[5] - Year-to-date revenue as of Q3 2022 totaled ¥844,841,561.52, reflecting a 20.62% increase compared to the same period last year[5] - Year-to-date net profit attributable to shareholders decreased by 45.21% to ¥78,911,121.91 due to increased costs and pandemic-related disruptions[5][10] - The basic earnings per share for Q3 2022 was ¥0.08, a decrease of 45.45% year-to-date[6][10] - The net profit for Q3 2022 was CNY 78,433,591.54, a decrease of 45% compared to CNY 142,829,123.17 in Q3 2021[26] - The total profit for Q3 2022 was CNY 98,292,856.77, down 48.9% from CNY 192,694,704.70 in the same period last year[26] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.18, compared to CNY 0.33 in Q3 2021, reflecting a decline of 45.5%[28] Cash Flow and Assets - The company reported a significant cash flow deficit from operating activities of -¥297,731,355.85 for the year-to-date period[6] - The company's cash and cash equivalents decreased to CNY 586,225,646.10 as of September 30, 2022, down 45.6% from CNY 1,077,382,405.31 at the end of 2021[20] - Cash and cash equivalents at the end of Q3 2022 were CNY 571,768,192.77, down from CNY 1,200,136,754.39 at the end of Q3 2021[31] - The total assets as of the end of Q3 2022 were ¥2,151,818,462.32, down 6.30% from the end of the previous year[6] - The total assets of the company as of September 30, 2022, were CNY 2,151,818,462.32, a decrease of 6.3% from CNY 2,296,495,401.64 at the end of 2021[22] - The total liabilities decreased to CNY 221,152,428.47 as of September 30, 2022, down 36.7% from CNY 349,662,959.33 at the end of 2021[22] Operational Challenges and Strategies - The company attributed the decline in net profit to increased R&D investments and rising raw material costs, along with pandemic-related operational challenges[10] - The company has implemented cost reduction and efficiency enhancement strategies to counteract rising raw material prices, optimizing its cost structure[14] - The company is focusing on new product development and channel expansion to drive future growth[10] - The company aims to enhance digital capabilities to support operational visualization and precision marketing, focusing on integrating online and offline customer experiences[18] Product Development and Market Strategy - The "Weidongli" ambient yogurt beverage business achieved both quarter-on-quarter and year-on-year revenue growth in Q3 2022[14] - The functional probiotic product matrix has been enriched, establishing initial product barriers for long-term strategic implementation[14] - New probiotic products, including the "Qingyou" and "Changyin" series, have shown significant growth, with the "Xianmeijun" series launched in the second half of the year[15] - The company is focusing on a dual-channel strategy to expand its market presence among first and second-tier consumers and new retail channels[17] - The company aims to become a globally competitive enterprise in the probiotic industry through strategic partnerships and supply chain integration[16] Research and Development - Research and development expenses for the first three quarters of 2022 were CNY 13,705,502.95, significantly higher than CNY 5,910,809.38 in the same period of 2021, reflecting a growth of 132.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,488[12] - The largest shareholder, Shanghai Junyao Group, holds 32.66% of shares, with 140,451,430 shares pledged[12]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 476,878,408.30, a decrease of 4.46% compared to CNY 499,144,455.02 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2021 was CNY 124,491,326.23, down 16.45% from CNY 149,003,499.05 in the previous year[18]. - Basic earnings per share for the first half of 2021 were CNY 0.29, down 29.27% from CNY 0.41 in the same period last year[20]. - The company reported a decrease of 26.51% in net profit after deducting non-recurring gains and losses, amounting to CNY 88,905,079.80 compared to CNY 120,980,277.01 in the previous year[18]. - The company achieved a revenue of RMB 476,878,408.30 and a net profit of RMB 124,491,326.23 during the reporting period[42]. - The company reported a total profit of RMB 59,414,296.86 for the first half of 2021, compared to RMB 57,304,040.08 in the same period of 2020, indicating a growth of 3.7%[145]. - The company’s total comprehensive income for the first half of 2021 was RMB 43,272,518.61, slightly higher than RMB 42,977,630.26 in the first half of 2020[146]. Cash Flow and Investments - The net cash flow from operating activities increased significantly to CNY 77,351,630.15, a 391.67% increase compared to CNY 15,732,316.90 in the same period last year[18]. - The company recorded a net cash inflow from investment activities of RMB 94,212,080.10, contrasting with a net outflow of RMB 17,684,657.61 in the first half of 2020[148]. - The company’s cash flow from financing activities was primarily impacted by dividend distributions amounting to 137,600,000.00 RMB[155]. - The company received 500,000,000.00 RMB from the recovery of investments during the first half of 2021, indicating strong investment management[150]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,225,019,132.51, reflecting a 2.45% increase from CNY 2,171,712,744.37 at the end of the previous year[19]. - Cash and cash equivalents at the end of the period amounted to ¥1,052,967,138.05, representing 47.32% of total assets, a slight increase of 2.05% compared to the previous year[61]. - Total liabilities amounted to CNY 299,994,866.10, compared to CNY 240,457,402.13, reflecting an increase of approximately 24.7%[134]. - The company's total assets decreased to CNY 1,723,911,957.26 from CNY 1,941,379,041.38 at the end of the previous period[138]. Research and Development - The company has invested significantly in R&D to enhance its production technology and ensure the stability and advancement of its processes[32]. - The company increased R&D investment by 340.22% year-on-year, totaling RMB 3,364,516.72, and added 3 new R&D personnel[43]. - Research and development expenses surged by 340.22% to ¥3.36 million, reflecting increased investment in R&D personnel and external collaborations[58]. - The company is focusing on innovation and product development, aiming to lead in the probiotics market and expand into new product categories[41]. Market Strategy and Operations - The company operates in the "Manufacturing of Dairy, Beverages, and Refined Tea" industry, specifically in the "Manufacturing of Dairy Beverages and Plant Protein Beverages" sector[24]. - The sales model primarily relies on a distribution strategy, targeting second and third-tier cities and expanding into county markets[30]. - The company has established a strong brand presence in the ambient yogurt market, with a competitive market share among first-tier brands[25]. - The company aims to gradually increase its self-owned production capacity to overcome existing scale bottlenecks[29]. Risks and Challenges - The company faces risks from intensified market competition in the ambient yogurt drink sector, which has seen rapid growth and high profit margins, attracting numerous brands[72]. - Raw material price fluctuations pose a significant risk, as key materials like skimmed milk powder and PE particles constitute a large portion of production costs, potentially impacting gross margins and profitability[72]. - The ongoing uncertainty from the COVID-19 pandemic continues to impact the supply chain, raw material prices, and consumer demand, leading to potential fluctuations in operational performance[72]. Corporate Governance and Compliance - The company has not faced any administrative penalties related to environmental issues and adheres to national environmental protection laws[80]. - The company has not disclosed any significant updates regarding its employee incentive plans or stock options during the reporting period[78]. - The company will comply with all relevant laws and regulations regarding share transfers and will accept supervision from regulatory bodies and investors[90]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 23,711[120]. - The top ten shareholders hold a total of 140,451,430 shares, representing 32.66% of the total shares outstanding[122]. - Wang Junjin, the actual controller of Shanghai Junyao Group, holds 103,995,000 shares, accounting for 24.18%[122]. Future Outlook - The company plans to launch a new dietary fiber-rich fresh fruit milk product in the second half of 2021 to expand its neutral milk beverage offerings[49]. - The company aims to enhance its online operations and product offerings, with a focus on private traffic operations and live streaming sales[51]. - The company will actively pursue capital operations to support its core business development and achieve exponential growth[55].